Profile data is unavailable for this security.
About the company
PureTech Health PLC is a clinical stage biotechnology company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.
- Revenue in GBP (TTM)7.86m
- Net income in GBP337.37m
- Incorporated2015
- Employees300.00
- LocationPureTech Health PLC501 Boylston St Ste 6102BOSTON 02116-3769United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttp://puretechhealth.com/
Mergers & acquisitions
| Acquired company | PRTC:LSE since announced | Transaction value |
|---|---|---|
| Ariya Therapeutics Inc | 7.45% | 666.98m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alliance Pharma plc | 135.64m | 25.01m | 396.17m | 219.00 | 15.82 | 1.44 | 14.85 | 2.92 | 0.0472 | 0.0472 | 0.2558 | 0.5179 | 0.3344 | 2.90 | 5.30 | 619,347.10 | 6.17 | 6.42 | 7.19 | 7.63 | 63.46 | 60.13 | 18.44 | 20.54 | 2.05 | 8.29 | 0.226 | 26.85 | 14.74 | 25.52 | 36.25 | 24.43 | 6.84 | -11.73 |
| Advanced Medical Solutions Group plc | 102.37m | 18.92m | 516.63m | 747.00 | 27.51 | 2.70 | 21.34 | 5.05 | 0.0872 | 0.0872 | 0.4721 | 0.8898 | 0.4737 | 2.58 | 3.63 | 137,038.80 | 8.75 | 11.40 | 9.57 | 12.50 | 59.08 | 59.56 | 18.48 | 20.13 | 5.48 | -- | 0.0514 | 13.34 | -0.2242 | 10.19 | -15.87 | 8.02 | 18.87 | 17.23 |
| Vectura Group PLC | 178.30m | -22.10m | 588.29m | 480.00 | -- | 1.42 | 18.38 | 3.30 | -0.0344 | -0.0344 | 0.2735 | 0.6859 | 0.3095 | 3.05 | 4.48 | 371,458.30 | -3.84 | -- | -4.35 | -- | 53.45 | -- | -12.39 | -- | 1.85 | -- | 0.0178 | -- | 11.09 | -- | 74.94 | -- | -- | -- |
| Oxford BioMedica plc | 64.06m | -16.07m | 621.10m | 500.00 | -- | 7.69 | -- | 9.70 | -0.225 | -0.225 | 0.881 | 0.984 | 0.5444 | 10.46 | 2.54 | 128,120.00 | -13.65 | -12.93 | -18.06 | -17.28 | 44.24 | 55.40 | -25.08 | -22.25 | 1.88 | -1.53 | 0.0999 | -- | -4.07 | 36.30 | -313.05 | -- | 35.82 | -- |
| Indivior PLC | 560.76m | -76.10m | 665.61m | 824.00 | -- | 21.30 | -- | 1.19 | -0.1105 | -0.1105 | 0.7445 | 0.0427 | 0.4492 | 1.63 | 3.49 | 680,537.60 | -6.10 | 11.73 | -11.18 | 30.58 | 82.86 | 88.38 | -13.57 | 14.99 | 1.63 | -- | 0.8796 | 12.38 | -21.89 | -6.78 | -50.92 | -19.77 | -23.08 | -- |
| Puretech Health PLC | 7.86m | 337.37m | 781.24m | 300.00 | 2.30 | 1.46 | 2.62 | 99.44 | 1.19 | 1.19 | 0.0273 | 1.88 | 0.0142 | -- | 5.93 | 26,187.63 | 52.94 | 4.21 | 66.31 | 6.05 | -- | -- | 3,732.69 | 163.04 | -- | -- | 0.057 | 0.00 | -52.73 | 34.57 | 1,064.73 | -- | 97.24 | -- |
| Clinigen Group PLC | 491.70m | 14.10m | 1.09bn | 130.00 | 78.74 | 2.46 | 16.68 | 2.21 | 0.1038 | 0.1038 | 3.68 | 3.32 | 0.5101 | 7.23 | 4.25 | 3,782,308.00 | 1.46 | 2.14 | 1.75 | 2.96 | 42.79 | 36.02 | 2.87 | 3.34 | 0.8647 | 6.89 | 0.451 | 54.53 | 19.86 | 29.26 | -81.02 | -20.34 | -2.90 | 16.67 |
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management Ltd.as of 31 Dec 2018 | 90.11m | 31.56% |
| Baillie Gifford & Co.as of 31 Dec 2018 | 25.42m | 8.91% |
| Jupiter Asset Management Ltd.as of 31 Dec 2018 | 18.36m | 6.43% |
| Canaccord Genuity Wealth Ltd.as of 01 Jun 2020 | 5.65m | 1.98% |
| M&G Investment Management Ltd.as of 01 Jun 2020 | 5.17m | 1.81% |
| Ruffer LLPas of 01 Jun 2020 | 4.65m | 1.63% |
| Bessemer Investment Management LLCas of 31 Jan 2020 | 2.71m | 0.95% |
| DNCA Finance SAas of 31 Dec 2019 | 2.30m | 0.81% |
| Legal & General Investment Management Ltd.as of 01 Jun 2020 | 2.22m | 0.78% |
| Majedie Asset Management Ltd.as of 30 Apr 2020 | 2.21m | 0.77% |
